Vanderbilt-Ingram Cancer Center
Henry-Joyce Cancer Clinic
Nashville, TN
Accepting patients
RENEW
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Activin Receptor IIA Inhibitor
- Closed Label (Masked)
- Placebo
- Phase 3
Accepting patients
AZTOUND
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
- DNMT1 Inhibitor
- Phase 2/3
- Has results
Accepting patients
PedAL Screening
Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
- Phase 1/2
Accepting patients
Eltanexor and Venetoclax
Phase Ib Study of Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
- SINE
- Phase 1
Accepting patients
ABNL-MARRO
The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes.
- Chemotherapy
- Phase 1/2
- Has results
Accepting patients
CROSSCHECK-001
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias (CROSSCHECK-001)
- T Cell Engager (TCE)
- Cathepsin G (CTSG)
- Phase 1
Accepting patients
Orca-T
A Phase 2 Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- T Cell (Allogeneic)
- Allogeneic Stem Cell Transplant
- Phase 2